These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 37840282)
1. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma. Hess G; Dreyling M; Oberic L; Gine E; Zinzani PL; Linton K; Vilmar A; Jerkeman M; Chen JMH; Ohler A; Stilgenbauer S; Thieblemont C; Lambert J; Zilioli VR; Sancho JM; Jimenez-Ubieto A; Fischer L; Eyre TA; Keeping S; Park JE; Wu JJ; Nunes A; Reitan J; Wade SW; Salles G Leuk Lymphoma; 2024 Jan; 65(1):14-25. PubMed ID: 37840282 [TBL] [Abstract][Full Text] [Related]
2. Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma. Anderson MK; Torosyan A; Halford Z Ann Pharmacother; 2022 May; 56(5):609-619. PubMed ID: 34340597 [TBL] [Abstract][Full Text] [Related]
3. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. Wang Y; Jain P; Locke FL; Maurer MJ; Frank MJ; Munoz JL; Dahiya S; Beitinjaneh AM; Jacobs MT; Mcguirk JP; Vose JM; Goy A; Andreadis C; Hill BT; Dorritie KA; Oluwole OO; Deol A; Paludo J; Shah B; Wang T; Banerjee R; Miklos DB; Rapoport AP; Lekakis L; Ghobadi A; Neelapu SS; Lin Y; Wang ML; Jain MD J Clin Oncol; 2023 May; 41(14):2594-2606. PubMed ID: 36753699 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England. Petersohn S; Salles G; Wang M; Wu J; Wade SW; Simons CL; Bennison C; Siddiqi R; Peng W; Kloos I; Castaigne G; Hess G J Med Econ; 2022; 25(1):730-740. PubMed ID: 35611697 [TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada. Ball G; Lemieux C; Cameron D; Seftel MD Curr Oncol; 2022 Mar; 29(3):2021-2045. PubMed ID: 35323364 [TBL] [Abstract][Full Text] [Related]
6. Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients. Shah B; Chen JMH; Wu JJ; Feng C; Zhou L; Park JE; Hadjiivassileva T; Kerbauy FR; Wade SW; Keeping S Adv Ther; 2023 Dec; 40(12):5383-5398. PubMed ID: 37801234 [TBL] [Abstract][Full Text] [Related]
7. Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. Mian A; Hill BT Expert Opin Biol Ther; 2021 Apr; 21(4):435-441. PubMed ID: 33566715 [No Abstract] [Full Text] [Related]
8. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Bouabdallah K; Khanal R; Topp MS; Houot R; Beitinjaneh A; Peng W; Fang X; Shen RR; Siddiqi R; Kloos I; Reagan PM J Clin Oncol; 2023 Jan; 41(3):555-567. PubMed ID: 35658525 [TBL] [Abstract][Full Text] [Related]
9. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. Deshpande A; Wang Y; Munoz J; Jain P Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706 [TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma. Marchetti M; Visco C Leuk Lymphoma; 2023; 64(8):1442-1450. PubMed ID: 37229538 [TBL] [Abstract][Full Text] [Related]
12. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Shah BD; Cassaday RD; Park JH; Houot R; Oluwole OO; Logan AC; Boissel N; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff PJ; Jeyakumar D; Mao D; Adhikary S; Zhou L; Schuberth PC; Damico Khalid R; Ghobadia A J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648261 [TBL] [Abstract][Full Text] [Related]
13. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Dong J; Adhikary S; Zhou L; Schuberth PC; Faghmous I; Masouleh BK; Houot R J Hematol Oncol; 2022 Dec; 15(1):170. PubMed ID: 36494725 [TBL] [Abstract][Full Text] [Related]
14. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Rejeski K; Wang Y; Albanyan O; Munoz J; Sesques P; Iacoboni G; Lopez-Corral L; Ries I; Bücklein VL; Mohty R; Dreyling M; Baluch A; Shah B; Locke FL; Hess G; Barba P; Bachy E; Lin Y; Subklewe M; Jain MD Am J Hematol; 2023 Nov; 98(11):1699-1710. PubMed ID: 37584447 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States. Simons CL; Malone D; Wang M; Maglinte GA; Inocencio T; Wade SW; Bennison C; Shah B J Med Econ; 2021; 24(1):421-431. PubMed ID: 33634729 [TBL] [Abstract][Full Text] [Related]
16. CAR T-Cell therapy for the management of mantle cell lymphoma. Huang Z; Chavda VP; Bezbaruah R; Dhamne H; Yang DH; Zhao HB Mol Cancer; 2023 Mar; 22(1):67. PubMed ID: 37004047 [TBL] [Abstract][Full Text] [Related]
17. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner. Munoz JL; Wang Y; Jain P; Wang M Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920 [TBL] [Abstract][Full Text] [Related]
18. Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer? McCulloch R Br J Haematol; 2023 Aug; 202(4):718-719. PubMed ID: 37188352 [TBL] [Abstract][Full Text] [Related]
19. FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Bouchkouj N; Lin X; Wang X; Przepiorka D; Xu Z; Purohit-Sheth T; Theoret M Oncologist; 2022 Oct; 27(10):892-899. PubMed ID: 35983953 [TBL] [Abstract][Full Text] [Related]
20. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma. Mohty R; Kharfan-Dabaja MA Ther Adv Hematol; 2022; 13():20406207221142133. PubMed ID: 36544864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]